Daridorexant vs Lemborexant — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Orexin Receptor Antagonist

Daridorexant

Brand: QUVIVIQ

First FDA approval: 2022-04-07

Orexin Receptor Antagonist

Lemborexant

Brand: DAYVIGO

First FDA approval: 2020-04-07

Lowest NADACAcquisition cost floor across all NDCs

$16.70Per unit

$11.57Per unit

Average NADACAcross all dosage forms and strengths

$16.71Up to $16.73

$11.58Up to $11.59

Generic manufacturersActive ANDA holders — FDA Orange Book

00 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$36.5MFull year

$32.5MFull year

Part D claims (CY24)Total fills, all strengths

69K21K beneficiaries

89K25K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$527Per claim, all NDCs

$365Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

38Minimal friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

2Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

NoBrand-only